Sg3 Management, LLC Chemo Centryx, Inc. Call Options Transaction History

Sg3 Management, LLC

$0
Q3 2023

Call Options

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $307,200 - $550,200	20,000 New	20,000 $496,000
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $362,186 - $637,656	-16,300 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$18.38 - $40.5 $4.29 Million - $9.44 Million	-233,200 Reduced 93.47%	16,300 $593,000
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $694,586 - $1.05 Million	-52,700 Reduced 17.44%	249,500 $4.27 Million
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $2.87 Million - $15.2 Million	299,500 Added 11092.59%	302,200 $4.05 Million
Q1 2021 May 17, 2021	SELL	$49.53 - $68.4 $2.72 Million - $3.76 Million	-54,900 Reduced 95.31%	2,700 $138,000
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $2.67 Million - $3.55 Million	57,600 New	57,600 $3.16 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg3 Management, LLC with notifications on news.